Arginine is considered a semi-essential amino acid because even though the body normally makes enough of it, supplementation is sometimes needed. For example, people with protein malnutrition, excessive ammonia production, excessive lysine intake, burns, infections, peritoneal dialysis, rapid growth, urea synthesis disorders, or sepsis may not have enough arginine. Symptoms of arginine deficiency include poor wound healing, hair loss, skin rash, constipation, and fatty liver.
Arginine changes into nitric oxide, which causes blood vessel relaxation (vasodilation). Early evidence suggests that arginine may help treat medical conditions that improve with vasodilation, such as chest pain, clogged arteries (called atherosclerosis), coronary artery disease, erectile dysfunction, heart failure, intermittent claudication/peripheral vascular disease, and blood vessel swelling that causes headaches (vascular headaches). Arginine also triggers the body to make protein and has been studied for wound healing, bodybuilding, enhancement of sperm production (spermatogenesis), and prevention of wasting in people with critical illnesses.
Arginine hydrochloride has a high chloride content and has been used to treat metabolic alkalosis. This use should be under the supervision of a qualified healthcare professional.
Cardium Therapeutics announced that it has gained exclusive access to commercial development rights for certain novel supramacromolecular polymer complexes enabling regulatable and localized topical delivery of nitric oxide for prolonged periods of one to three weeks, to broaden and expand the Company's wound healing and tissue regeneration portfolio.
Researchers in Cedars-Sinai's Department of Psychiatry and Behavioral Neurosciences have reported people who undergo massage experience measureable changes in their body's immune and endocrine response.
Richard Lamb and his post doctoral fellow Virginie Mieulet, in the Faculty of Medicine & Dentistry, may be able to explain why proper nutrition is so vital in fighting infection.
The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.
Research from the University of Exeter has revealed taking a dietary supplement to boost nitric oxide in the body can significantly boost stamina during high-intensity exercise.
ForeverGreen Worldwide Corp., manufacturer and distributor of all natural whole foods, today announced that it has filed 2010 Q2 financial reports.
Researchers have developed an improved coating technique that could strengthen the connection between titanium joint-replacement implants and a patients' own bone. The stronger connection created by manipulating signals the body's own cells use to encourage growth could allow the implants to last longer.
In 2004, Washington University in St. Lous researcher Jianmin Cui was handed a puzzling clue to the structure of an ion channel his lab had been studying for five years.
Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.
Physicians attending the annual meeting of the American Society of Clinical Oncology (ASCO) presented evidence that pegylated arginine deiminase (ADI-PEG 20), a novel anticancer drug that targets ASS(-) tumors, and which is being developed and manufactured by Polaris Group, was effective in inhibiting the growth of metastatic melanoma cells.
ForeverGreen Worldwide Corp., a manufacturer and distributor of all natural whole foods, today announced that its 2010 Q1 filing reports positive cash flow from operations.
ARCA biopharma, Inc. today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a clinical trial to assess the safety and efficacy of bucindolol in approximately 3,200 patients with chronic heart failure who have the genotype that appears to respond most favorably to bucindolol. Bucindolol is the Company's investigational, pharmacologically unique, beta-blocker and mild vasodilator.
Polaris Group scientists and university collaborators reported at the American Association for Cancer Research (AACR), that a number of different cancers have a deficiency in a specific enzyme, argininosuccinate synthetase (ASS), which allows pegylated arginine deiminase (ADI-PEG 20) to inhibit cancer cell growth.
ForeverGreen Worldwide Corp. today announced fourth quarter and its 2009 full year financial results.
Researchers have shown that a peptide (a chain of amino acids) called iRGD helps co-administered drugs penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment efficacy against human breast, prostate and pancreatic cancers in mice, achieving the same therapeutic effect as a normal dose with one-third as much of the drug.
ForeverGreen Worldwide Corp. announces the completion of its in-house fully functional information systems.
Taking arginine supplements can improve the cycling ability of over-50s. Researchers writing in BioMed Central's Journal of the International Society of Sports Nutrition tested a combination of the amino acid and an antioxidant in sixteen cyclists, finding that it enhanced their anaerobic threshold - the amount of work done before lactic acid begins to accumulate in the blood
Leading insect vector biologists from around the world will gather at the University of California, Riverside for two days this month to discuss their latest research on vector-borne diseases in humans and plants.
ForeverGreen Worldwide Corp. has already been experiencing significant indicators for growth in their worldwide markets for this year. Analyzing the company’s first two weeks of business in January compared to the first two weeks in February, the company boasted a growth rate of approximately 19 percent.
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Cayston® (aztreonam for inhalation solution) as a treatment to improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa. Cayston’s safety and efficacy have not been established in pediatric patients below the age of 7, patients with forced expiratory volume in one second of less than 25 percent or greater than 75 percent predicted, or patients colonized with Burkholderia cepacia.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.